Trial Profile
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Dec 2023
Price :
$35
*
At a glance
- Drugs Pamrevlumab (Primary)
- Indications Hepatic fibrosis; Hepatitis B
- Focus Therapeutic Use
- Sponsors FibroGen
- 14 Nov 2023 Results assessing long-term HBsAg seroclearance presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 12 Aug 2016 Status changed from active, no longer recruiting to discontinued.
- 06 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.